Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Breakthrough Therapy designation filing possible if more patients show similar positive results VANCOUVER, Washington, Nov. 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 […]
FSD Pharma Announces Strategic Investment in Huge Shops – Huge Shops forms alliance with Coffee Time’s parent company Chairman’s Brands to establish retail distribution network – TORONTO—FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: […]
Nigam Arora: The Coming “Canadian Marijuana Stocks Massacre”. Nigam discusses his long term outlook for cannabis stocks… He expects cannabis stocks focused on the Canadian market to lose 90% value, as market realities set in. […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
